Disease State: Lichenoid dermatoses
Background
Lichenoid diseases are a group of chronic inflammatory dermatoses that can affect any part of the integument, including the skin, mucous membranes, nails, and hair. This is also true for lichen planus (LP), one of the main subtypes of lichenoid disease.
Cutaneous lichen planus (CLP) is associated with a significant symptom burden that may include itch, pain or a burning sensation. The disease often leaves behind disfiguring pigmentary changes, and in some cases scarring. As such, CLP can have a substantial impact on patients’ quality of life and has been linked to psychological comorbidities such as anxiety and depression. There are no regulatory approved treatment for CLP, and drug development may be hampered by the lack of a core outcome set (COS) that includes well validated outcome measurement instruments that can highlight the improvements in physical signs, symptoms and life impact with adequate treatment, and that can be used to compare efficacy across treatments.
Project Goal
LiCOS (Lichenoid Core Outcomes Set) aims to address this gap by bringing together experts, methodologists, patients, and industry partners from around the world to develop a COS for CLP (LiCOS-CLP). This COS will help ensure that future clinical trials for CLP evaluate domains that are meaningful to stakeholders by way of instruments that demonstrate robust performance.
COS Progress Meter
Project Leads
Sanne E Uitentuis
Amit Garg
Steering Members
Kamran Ghoreschi
Zach Hopkins
Matilde Iorizzo
Kristen Losicco
Aaron Mangold
Sheila Shaigany
Matthew Vesely
Key Project Team Members
Alex Silberzweig
Andrew Strunk
Alexander Velaoras
C3 Methods Partner
Phyllis Spuls
Contact
Sanne E Uitentuis, s.e.uitentuis@amsterdamumc.nl
Publications
Pelet Del Toro N, Strunk A, Garg A, Han G. Prevalence and treatment patterns of lichen planus. J Am Acad Dermatol. 2025;92(4):717-723. PMID: 39579991
Pelet Del Toro N, Strunk A, Garg A, Han G. Prevalence and Treatment Patterns in Patients With Lichen Planopilaris. JAMA Dermatol. 2024;160(8):865-868. PMID: 38865116
Cho C, Haddadi NS, Kidacki M, Woodward GA, Shakiba S, Yildiz-Altay U, Richmond JM, Vesely MD. Spatial transcriptomics in inflammatory skin diseases using GeoMx digital spatial profiling: a practical guide for applications in dermatology. JID Innovations. 2024, Sep 37;5(1). PMID: 39559817
Kidacki M, Cho C, Lopez-Giraldez F, Breidbart R, Jaiswal A, Damsky W, Chen L, Vesely MD. Spatial transcriptomics reveals differential inflammatory pathways in discoid lupus erythematosus and lichen planus. Journal of Investigative Dermatology.2025 March 18: PMID: 40113031
Richmond RL, Murphy MJ, Edemobi P, Vesely MD, Cohen JM. Association of Lichen Planus with Asthma and Allergic Rhinitis in the All of Us Research Program: A Cross-Sectional Study. Clinical and Experimental Dermatology. 2024, April 9. PMID: 38589773, doi: 10.1093/ced/llae101
Park J, Park E, Damsky W, Vesely MD. Pembrolizumab-induced lichenoid dermatitis treated with dupilumab. JAAD Case Reports. 2023, 37: 13-15. DOI: 10.1016/j.jdcr.2023.05.004.
Updated on November 19, 2025